Drug Search Results
More Filters [+]


Alternative Names: AFNT-111, AFNT111, AFNT 111
Latest Update: 2024-05-28
Latest Update Note: News Article

Product Description

AFNT-111 is a T-cell therapy being developed by AffiniT Therapeutics to target and treat cancers with a KRAS G12V mutation. (Sourced from: https://affinittx.com/wp-content/uploads/Affini-T_Non-Confidential_Deck_Jefferies_June-2022.pdf)

Mechanisms of Action: Cell Therapy

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AffiniT Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AFNT-111

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified



Trial Status


Primary Completion Date

Probability of Success

Recent News Events